Brenus Pharma Information

Brenus is a clinical stage biotech company developing new “in vivo” immunotherapy modality for solid tumors, derived from a fully off-the-shelf platform approach. Our proprietary SGC (Stimulated Ghost Cell) technology makes tumor cells visible, training the immune system in vivo to mount a multi-specific response, built to adapt as the tumor evolves. Our lead asset, STC-1010, is an in vivo immunotherapy (DC-engager) that educates the own patient’s immune system against 200+ targets validated via multi-omics. It is being evaluated in a Phase I/II trial in Europe (NCT06934538) as frontline treatment for MSS metastatic colorectal cancer, a population resistant to current immunotherapies. Our US IND is effective. Beyond colorectal cancer, the platform has the potential to bring precision oncology at scale being the missing link in imuno-oncology for solid tumors. Headquartered in Lyon, France, with an R&D site in Liège, Belgium. €38M raised to date from international investors and Bpifrance.